Safety and pharmacokinetics of BI 685509, a soluble guanylyl cyclase activator, in patients with cirrhosis: A randomized Phase Ib study.

MLA

Lawitz, Eric J., et al. “Safety and Pharmacokinetics of BI 685509, a Soluble Guanylyl Cyclase Activator, in Patients with Cirrhosis: A Randomized Phase Ib Study.” Hepatology Communications, vol. 7, no. 11, Nov. 2023, pp. 1–14. EBSCOhost, https://doi.org/10.1097/HC9.0000000000000276.

APA

Lawitz, E. J., Reiberger, T., Schattenberg, J. M., Schoelch, C., Coxson, H. O., Wong, D., & Ertle, J. (2023). Safety and pharmacokinetics of BI 685509, a soluble guanylyl cyclase activator, in patients with cirrhosis: A randomized Phase Ib study. Hepatology Communications, 7(11), 1–14. https://doi.org/10.1097/HC9.0000000000000276

Chicago

Lawitz, Eric J., Thomas Reiberger, Jörn M. Schattenberg, Corinna Schoelch, Harvey O. Coxson, Diane Wong, and Judith Ertle. 2023. “Safety and Pharmacokinetics of BI 685509, a Soluble Guanylyl Cyclase Activator, in Patients with Cirrhosis: A Randomized Phase Ib Study.” Hepatology Communications 7 (11): 1–14. doi:10.1097/HC9.0000000000000276.